Clinical Study begins on Insulin Delivery Device for Type 2s

all

technology

life sciences

June 16, 2012
Clinical Study begins on Insulin Delivery Device for Type 2s

Article published about CeQur on DiabetesHealth.com

A clinical study has begun of a wearable device that continuously delivers basal insulin to people with type 2 diabetes. The device, PaQ®, is manufactured by CeQur SA, a Swiss company that has operations in Denmark and Massachusetts. Designed to provide three days of basal insulin delivery along with on-demand bolus insulin, the device incorporates a disposable insulin infuser reservoir attached to a reusable insulin monitor.

The clinical study, led by Professor Thomas Pieber, head of the Division of Endocrinology and Metabolism at the University Hospital Graz, Austria, will determine if the device can successfully deliver daily insulin to type 2 users. Pieber will be looking at safety, patient satisfaction, and glycemic control.

According to CeQur, 11 million type 2s in the European Union and the United States take insulin to manage their disease. When multiple daily injections are required, however, half of all patients skip doses, citing inconvenience, embarrassment, pain, and disruption of their daily routine. CeQur's hope is that a discreet continuous insulin infusion will increase the percentage of type 2s who adhere to an insulin regimen.

More information about the device is available at www.cequrcorp.com.

back

		"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG
		"In preparing for our dual IPOs on the Nasdaq and Neuer Markt, it was very important for SCM Microsystems to gain insight and access to the European investment scene. This team helped SCM build the foundation for our successful offerings not only with capital, but with sound guidance and value-added services as well." Robert Schneider, founder and CEO, SCM Microsystems Inc.
		"VC is about funding your project but it is more about extending your core team. Thus, it is about partnering with those who are great to work with and are team players. Those, who understand your business and embrace your vision. Those, who know how to challenge your execution and to bring value. This is why I recommend Endeavour Vision team to entrepreneurs looking for funding." Dr. Georges Karam, co-Founder, President & CEO, Sequans
		"With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick. They are highly professional partners and support us in every possible manner." Christian Lindner, Co-Founder and CEO Retailo AG
		"We wanted a Venture Capital investor who was prepared to share our vision to create a global European company. The quality of their track record, the way they are helping us take our company to the next level, and the pure scale of their ambition make them a pleasure to work with." Boris Saragaglia, CEO, Spartoo.com
		"Not only do Endeavour Vision partners demonstrate relentless long term support standing strong and reliable leading shareholders, but they also bring tremendous value by cross-fertilizing upcoming technologies if and when they make business sense." Claude Cosson, CEO, Perigee
		"Entrepreneurs tend to avoid as much as possible VC's but if you really need smart Venture money then put Endeavour Vision on the top of your list: they are smart, knowledgable, experienced and well connected." Fédéric Koehn, CEO, Neocutis
		"Endeavour Vision's team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360° due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is "smart money" at its best." Jacques R. Essinger, CEO Symetis
		"The Endeavour Vision team has been very helpful to BIND on multiple levels. Their advice, contacts and support rank with the best." Scott Minick, CEO, BIND Biosciences